MedTrace Logo

Glucocorticoid on the Prognosis of TEVAR

NCT02523300 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2015-08-14

No results posted yet for this study

Summary

To explore the potential prognostic effect of glucocorticoid on the postoperative aorta-related adverse events after aortic dissections patients underwent thoracic endovascular aortic repair (TEVAR), glucocorticoid (30mg/kg) will be intravenously given within 2h after TEVAR.

Conditions

  • Aortic Dissection

Interventions

PROCEDURE

TEVAR

The patients will be undertaken TEVAR

DRUG

Glucocorticoids

About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group

DRUG

saline

The other 120 patients will be given saline as control group

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zaiping Jing, Doctor · Department of Vascular Surgery, Changhai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-09-30
Completion
2019-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02523300 on ClinicalTrials.gov